SEQSTER and PatientsLikeMe Launch National Rare Disease Study

SEQSTER and PatientsLikeMe Launch National Rare Disease Study

One of the first rare-disease studies focused on Alpha-1 Antitrypsin Deficiency has been launched thanks to a partnership between SEQSTER PDM, Inc. ("SEQSTER") and PatientsLikeMe (PLM), leaders in patient-centric healthcare data technologies and patient engagement (AATD). The goal of the project is to gain a greater understanding of how enhanced digital real-time data, peer support, and practical evidence can be used to diagnose patients with AATD more quickly, reduce care inequities, and improve patient outcomes. Chris Renfro-Wallace, Chief Operating Officer of PatientsLikeMe, said, "We have been working with SEQSTER for the past year building a best-in-class operating system to empower rare disease patients and researchers with longitudinal health data in real-time." "With the help of this study, SEQSTER and PLM have a rare opportunity to combine diverse patient health data on a single platform and increase involvement with the study."

Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.

© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 28, 2024 at 11:33am